Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R33HL157804 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
| Society of Hospital Medicine | OTHER |
Not provided
Not provided
Not provided
Not provided
This study's objective is to identify and test pragmatic and sustainable strategies for implementing a multi-condition clinical pathway intervention for children hospitalized with asthma, pneumonia, or bronchiolitis in community hospitals. The hypothesis is that the multi-condition pathway intervention will be associated with significantly greater increases in clinicians' adoption of evidence-based practices compared to control. The study is a pragmatic, cluster-randomized trial in US community hospitals. The primary outcome will be adoption of evidence-based practices over a sustained period of 2 years. Secondary outcomes include length of hospital stay, intensive care unit transfer, and hospital readmission/emergency department revisit.
Asthma, pneumonia, and bronchiolitis are the top causes of childhood hospitalization in the US, leading to approximately 350,000 hospitalizations and $2 billion in costs annually. Poor guideline adoption by clinicians contributes to poor health outcomes for children hospitalized with these respiratory illnesses, including longer recovery time/hospital stay, higher rates of transfer to intensive care units, and increased risk of hospital readmission.
Pathways can improve clinicians' adoption of evidence-based practices/guidelines in both children's and community hospital settings. Pathways are simple, visual diagrams that guide clinicians step-by-step through the evidence-based care of a specific medical condition (accessed via paper or electronically). Most hospitals implement pathways for a single medical condition at a time (e.g., asthma). But Seattle Children's Hospital developed an intervention for simultaneously implementing pathways for multiple conditions. This intervention led to sustained guideline adoption, decreased length of stay, and decreased costs; and, these effects were comparable to those shown with single-condition pathway implementation. This multi-condition pathway intervention has not yet been studied in community hospitals, which face unique implementation barriers.
The study's objective is to identify and test pragmatic and sustainable strategies for implementing a multi-condition pathway intervention for children hospitalized with asthma, pneumonia, or bronchiolitis in community hospitals. The study is a pragmatic, cluster-randomized trial in US community hospitals. The pathway intervention will be implemented using the key implementation strategies defined for this intervention (audit and feedback, electronic health record integration, plan-do-study-act cycles). The primary outcome will be adoption of evidence-based practices over a sustained period of 2 years. Secondary outcomes include length of hospital stay, intensive care unit transfer, and hospital readmission/emergency department revisit.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multi-condition Pathway Intervention | Experimental | The multi-condition pathway intervention consists of pathways clinicians select from to guide the care of children with asthma, pneumonia, or bronchiolitis. Key implementation strategies include audit and feedback, plan-do-study-act cycles, electronic order sets, and mentoring/facilitation. |
|
| Standard of Care | No Intervention | Hospitals randomized to the control arm will not receive the multi-condition pathway intervention or any external supports for implementation. They will continue to provide current standards of care. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Multi-condition Pathway Intervention | Behavioral | See Experimental/Arm 1 description |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pneumonia Evidence Based Practice 1 | Administration of narrow spectrum antibiotic | During a hospitalization, approximately 2 days |
| Pneumonia Evidence Based Practice 2 | No prescription of macrolide antibiotics | During a hospitalization, approximately 2 days |
| Asthma Evidence Based Practice 1 | Prescription of inhaled corticosteroids for children greater than or equal to 5 years-old | During a hospitalization, approximately 2 days |
| Asthma Evidence Based Practice 2 | Use of metered-dose inhalers | During a hospitalization, approximately 2 days |
| Asthma Evidence Based Practice 3 | Use of an asthma pathway/bronchodilator weaning protocol | During a hospitalization, approximately 2 days |
| Bronchiolitis Evidence Based Practice 1 | No administration of albuterol | During a hospitalization, approximately 2 days |
| Bronchiolitis Evidence Based Practice 2 | No chest radiographs | During a hospitalization, approximately 2 days |
| Measure | Description | Time Frame |
|---|---|---|
| Length of Hospital Stay | Length Hospital Stay | During a hospitalization, approximately 2 days |
| Transfer to Intensive Care | The event of patient being transferred to an ICU |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sunitha V Kaiser, MD, MSc | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94153 | United States |
Data generated under this project will be administered in accordance with the policies of the University of California San Francisco (UCSF) and NIH/NHLBI. The Final Research Data (the dataset necessary to document and support research findings) will be made available for sharing after the main research findings from the final data set have been accepted for publication in a peer-reviewed journal. Prior to sharing, data will be redacted to strip all direct identifiers of hospitals (no identifiers of patients/individuals will be collected).
The data will become available after peer-reviewed publication, and it will be available for 3 years.
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Sep 11, 2025 | Sep 11, 2025 | Prot_SAP_ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| D011014 | Pneumonia |
| D001988 | Bronchiolitis |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Participating hospitals will be randomized into either an intervention group (will test simultaneous implementation of 3 clinical pathways) or control (will continue to provide standard care)
Not provided
Not provided
Participants, clinicians, and investigators cannot be masked due to the nature of the intervention. However, outcomes assessors will be masked.
| During a hospitalization, approximately 2 days |
| 30-day Hospital Readmission or Emergency Department Revisit | Event of a patient being readmitted to hospital or having an emergency department visit within 30 days of hospital discharge | 30 days after hospital discharge |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D001991 | Bronchitis |